As with the subcutaneous administration of any peptide, the subject may experience minor, injection-related side effects such as swelling and redness at the injection site
In severe osteoarthritis, the limiting problem is often structural joint degeneration
Disruptions in the NVU, leading to BBB dysfunction and reduced CBF, are early events in various neurodegenerative diseases, including AD, PD, and ALS [85]
Research suggests the peptide works through hormetic mechanisms where lower doses may trigger stronger adaptive healing responses in certain tissue types
In search of weight loss drugs, without the high prices or FDA oversight Around 2023, GLP-1 knock-offs entered the mainstream via regulated, US-based compounding pharmacies